Matsuzaka, Takashi, Kuba, Motoko, Koyasu, Saori, Yamamoto, Yuta, Motomura, Kaori, Arulmozhiraja, Sundaram, Ohno, Hiroshi, Sharma, Rahul, Shimura, Takuya, Okajima, Yuka, Han, Song-Iee, Aita, Yuichi, Mizunoe, Yuhei, Osaki, Yoshinori, Iwasaki, Hitoshi, Yatoh, Shigeru, Suzuki, Hiroaki, Sone, Hirohito, Takeuchi, Yoshinori, Yahagi, Naoya, Miyamoto, Takafumi, Sekiya, Motohiro, Nakagawa, Yoshimi, Ema, Masatsugu, Takahashi, Satoru, Tokiwa, Hiroaki, Shimano, Hitoshi
Hepatology (Baltimore, Md.) 71(5) 1609-1625 2020年5月
Dysfunctional hepatic lipid metabolism is a cause of non-alcoholic fatty liver disease (NAFLD), the most common chronic liver disorder worldwide, and is closely associated with insulin resistance and type 2 diabetes (T2D). ELOVL fatty acid elongase 6 (Elovl6) is responsible for converting C16 saturated and monounsaturated fatty acids (FAs) into C18 species. We have previously shown that Elovl6 contributes to obesity-induced insulin resistance by modifying hepatic C16/C18-related FA composition. To define the precise molecular mechanism by which hepatic Elovl6 affects energy homeostasis and metabolic disease, we generated liver-specific Elovl6 knockout (LKO) mice. Unexpectedly, LKO mice were not protected from high-fat diet-induced insulin resistance. Instead, LKO mice exhibited higher insulin sensitivity than controls when consuming a high-sucrose diet (HSD), which induces lipogenesis. Hepatic patatin-like phospholipase domain-containing protein 3 (Pnpla3) expression was downregulated in LKO mice, and adenoviral Pnpla3 restoration reversed the enhancement in insulin sensitivity in HSD-fed LKO mice. Lipidomic analyzes showed that the hepatic ceramide(d18:1/18:0) content was lower in